Acute myeloid leukaemia (AML) is a much more complex and resistant disease than the lymphoblastic variant, although progress in recent years has resulted in a third of such patients being long-term survivors (Lie, 1989; Boulad & Kernan, 1993; Ravindranath & Schultz, 1994) . In an article on U.S.A. Childhood Cancer Survival in 1973-87, AML was said to be the childhood tumour with the worst prognosis (Novakovic, 1994) . The majority of studies published are based on institutional patients and the real impact of the disease at population level is largely unknown.
In the Nordic countries (Denmark, Finland, Iceland, Norway and Sweden) there is a unique possibility to perform population-based studies and to trace patients for follow-up. A common registry for children with acute lymphoblastic leukaemia (ALL) was established in 1981 and for children with acute myelogenous leukaemias in 1984 by the Nordic Society of Paediatric Hematology and Oncology (NOPHO). We have now documented information on every case of any childhood leukaemia in our population of 23 million inhabitants .
In this study we present data on all the children diagnosed with AML in the Nordic countries over a period of 8 . 5 years. Both epidemiologic features and treatment results are described. In this period we have run two consecutive trials, with the second protocol (NOPHO-88) being more intense because resistant disease was the major problem in the first protocol (NOPHO-84). closed on 31 December 1992 and analysis performed on data collected during January 1995.
The diagnosis of AML was based on the presence of >25% abnormal blasts or promyelocytes as defined by regular staining, histochemistry, immunophenotyping or chromosome analysis when possible. With five countries involved, it was impossible to have a central review, but the diagnostic criteria were the same in all countries. Therapy was centralized to the University Hospitals and included 21 centres.
Therapy. An outline of the first protocol (NOPHO-84) is shown in Fig 1. Induction therapy consisted of three courses including bolus cytarabine (Ara-C), 6-thioguanine and doxorubicin given as an infusion on day 5. CNS prophylaxis with intrathecal methotrexate was given on the first day of each course in age-based dosages. Consolidation therapy consisted of high-dose Ara-C only (2 g/m 2 q12 h days 1, 2 and 3) repeated four times with a 3-4-week interval and with methotrexate intrathecally as during induction.
The therapy given in NOPHO-88 is shown in Fig 2. Therapy was intensified through the addition of etoposide and mitoxantrone both during induction and consolidation. Drug details are given in the figure. If the condition of the child allowed, course 2 was given not more than 2 weeks after course 1. During consolidation, VP-16 was given as an infusion over 1 h. In both induction and consolidation, mitoxantrone was given as an infusion lasting 30 min. Doxorubicin was given over 8 h.
Transplantation with allogeneic bone marrow was offered to all patients where an HLA-identical family donor was available. During the course of the study some centres started autologous bone marrow transplantation, but never before the second consolidation course. A conditioning regime consisting of busulfan and cyclophosphamide was used in the majority of patients with the remaining patients receiving total body irradiation (TBI) and cyclophosphamide according to the protocol of the bone marrow transplant centre involved. Patients with Down's syndrome were offered the same chemotherapy as other children. However, especially at the beginning of the period, many parents declined chemotherapy for their child with trisomy 21. Statistical methods. Statistical analyses were performed with SPSS statistical software (Norusis, 1992) . Survival curves were performed using the Kaplan-Meier method (Kaplan & Meier, 1958) and remission durations for subgroups were compared with the log-rank test (Mantel, 1966) . Cox multivariate proportional hazard regression analyses were performed for evaluating prognostic factors (Cox, 1972) .
RESULTS

Epidemiology
Of the 1665 children diagnosed with acute leukaemia in the Nordic countries, 272 patients were classified as acute myelogenous leukaemias (Table I ). The proportion of ALL to AML was similar in all countries. Therefore the annual incidence of AML was 0 . 7 new cases per 100 000 children aged <16 years.
In contrast to many other studies (Neglia & Robison, 1988; Boulad & Kernan, 1993) , there were more girls than boys in our series (M:F ratio 0 . 8). A peak incidence was seen in the first 2 years of life. Of the 272 patients, 35 had Down's syndrome (13%). The age-specific incidence in patients with Down's syndrome was strikingly different from the others. Of the 35 patients, 33 were diagnosed between 1 and 3 years of age. Table II presents the overall results of our study. Of the 272 patients registered, 33 were excluded from further analysis for reasons indicated in the table.
Treatment outcome
Sixteen patients were treated with a variety of other protocols, especially in the first years of NOPHO-84; of these, only four are long-term survivors. There was no selection by sex, age or other risk features in this group.
This leaves 223 patients treated according to NOPHO-84 and NOPHO-88. Patients' characteristics are listed in Table  III Allo., allogeneic transplant; ABMT 1; autologous bone marrow transplant; Cyto.; chemotherapy alone; MUD, matched urelated donor; N-84, protocol NOPHO-84; N-88, protocol NOPHO-88; CCR, continuous complete remission. remission (78%). Eight patients died in aplasia, and 15 patients had resistant disease. Of the 118 patients on NOPHO-88, 100 (85%) achieved a remission, the failures being 14 children dying in aplasia, whereas only four had resistant disease. Thus, the pattern of failure was reversed and we observed no significant difference between the overall induction results.
None of our patient characteristics appeared to predict for a better or a worse induction outcome, including WBC count, FAB type or age. Girls had a slightly inferior induction outcome, but not significantly so.
The results according to post-remissiontherapy are listed in Table II . Of the 27 patients who received allogeneic transplant, 15 (55%) are at present in their first remission.
Of the 33 patients treated with an autologous bone marrow transplant, 14 (42%) are in their first remission. There was no selection of patients for transplant based on risk features. One child with Down's syndrome received an autologous transplant. Of the 120 children who received chemotherapy alone, 55 (50%) are disease-free. The probabilities of remaining in remission are presented in Figs 3-6.
Prognostic factors
Since there are no significant differences between the patient population in the two studies (Table III) and treatment outcome, it was possible to pool patient data before looking for prognostic factors. Several clinical and laboratory characteristics were examined as potential markers of outcome in this population-based study.
Cox analyses were performed on all 223 children with regard to age, Hb, WBC, FAB, gender, year of diagnosis and Down's syndrome. These factors were also analysed for children who achieved remission. Gender was found to be the only significant prognostic factor (P 0 : 01). If only children with achieved remission were analysed, the factors with prognostic significance were Down's syndrome (P < 0 : 01) and gender (P 0 : 01). Of 23 children with Down's syndrome receiving appropriate chemotherapy, 17 went into remission and 13 are long-term survivors (p-DFS 0 . 79). This leukaemia is more responsive to treatment than the disease attacking non Down's syndrome children.
Gender was the only significant prognostic factor we observed (Fig 6) . In both protocols females had a better prognosis. After the two studies were combined and the Down's children were excluded, p-EFS for girls was 0 . 43 v 0 . 26 for boys (P Age at diagnosis did not strongly associate with outcome, the time to obtain remission or duration of the first remission. The prognosis was worst in patients aged between 1 and 2 years; only 35% of these patients remain in CCR. Of the infants <12 months of age, 58% remain in CCR. However, this difference is not statistically significant.
Other prognostic factors were not found. In contrast to many other studies, high white blood cell count at diagnosis did not influence treatment outcome.
DISCUSSION
We have presented data on all children with AML diagnosed in the five Nordic countries from July 1984 through to December 1992. The incidence was similar within the five countries with an annual incidence of 0 . 7 new cases per 100 000 children aged <16 years. When compared with other series (Neglia & Robison, 1988; Boulad & Kernan, 1993) , it is surprising that we have a definite age peak in the first 2 years of life. This is explained partly by the high frequency of children with Down's syndrome in this age group. 35 of the patients (13%) had Down's syndrome and only one was <12 months of age. This is a much higher incidence than reported elsewhere. In the large German and Italian studies (Creutzig et al, 1990 (Creutzig et al, , 1993 Amadori et al, 1993) , children with Down's syndrome are probably not included. In the U.K., 5 . 1% of children with AML are reported to have Down's syndrome (Stiller & Eatock, 1994) , and a large survey conducted by the Childrens Cancer Group (CCG) in the U.S.A. reported 2% of AML cases to be Down's syndrome (Robison et al, 1984) . In a Pediatric Oncology Group material, 12/285 children (4%) had Down's syndrome (Ravindranath et al, 1992) . This discrepancy between our finding and other studies might reflect the fact that our study is population-based where every case is recorded.
The incidence over the years was similar, with about 30 new cases annually. The distribution of important disease characteristics, except for age and Down's syndrome, was not different from other series (Table III) .
The two protocols used varied in intensity with NOPHO-88 being on the borderline of acceptable toxicity. Long-lasting aplasia followed the induction regimen in all treated children. Death in aplasia was seen in 12% in NOPHO-88 and 8% in NOPHO-84. Of even greater concern was that 10 children died in CCR after consolidation therapy in NOPHO-88, whereas only one child died after consolidation in NOPHO-84. Therefore the addition of etoposide and mitoxantrone did not improve the overall results due to these complications. Autologous bone marrow transplantation was added to the protocol in some centres. The overall results in this group were not better than in the group receiving conventional chemotherapy. Patients treated with allogeneic transplantation may turn out to have a better prognosis than patients treated with chemotherapy alone, but so far the difference is not statistically significant (Fig 5) . Since bone marrow transplantation was not done in a randomized fashion, the effect of these therapies must be left open.
The strongest significant prognostic factor found in our study was the effect of gender (Fig 6) . After obtaining remission, girls did significantly better than boys in both protocols. This effect of gender has not been detected in other studies of childhood AML, but we have previously reported on a remarkable effect of gender on high-risk ALL, with girls doing much better than boys (Lanning et al, 1992) .
It is now a well-established fact that children with Down's syndrome developing AML have a disease which is more responsive to aggressive chemotherapy (Ravindranath et al, 1992; Slordahl et al, 1992 Slordahl et al, , 1993 Zipursky et al, 1992) . A large number of cases appear to be of a distinct subtype related to M7 and with markers from several lineages on their malignant cell surface (Slordahl et al, 1992 (Slordahl et al, , 1993 .
NOPHO-84 had a simple consolidation therapy consisting exclusively of four courses of high-dose Ara-C with no other drugs added (Lie et al, 1990) . The fact that the addition of etoposide and mitoxantrone (NOPHO-88) did not improve the treatment results suggest that more is not necessarily better. We observe that toxicity problems outweigh the possible benefit of the intensified therapy. Our current protocol takes this into consideration, since every child will receive the first induction course of NOPHO-88 and then remain without therapy until the child either achieves a remission or persistent disease is documented. Non-responders will then proceed to the intensified therapy with mitoxantrone and etoposide as in NOPHO-88, whereas in responders induction course 1 will be repeated. In this way we hope to reduce the toxicity by limiting the most aggressive therapy to the most resistant disease.
Our results compare favourably with other reported studies. The largest studies are presented in Table IV (Creutzig et al, 1990 (Creutzig et al, , 1993 Ravindranath et al, 1991; Amadori et al, 1993; Woods et al, 1993; Nesbit et al, 1994; Stevens et al, 1994; Wells et al, 1994) . One of the most challenging preliminary reports is that of the timed intensive induction therapy reported by Woods et al (1994) . Their very intensive induction did not improve the percentage of children entering remission, but certainly improved postremission outcome, regardless of post-remission therapy. Their results are in conflict with ours, where NOPHO-88 is an example of a very intensive 'up-front' therapy, but where problems of toxicity outweigh the benefit of increased therapy. Otherwise it is remarkable (Table IV) that most of the studies are comparable in terms of the proportion of long-term survivors. Extensive Table IV 
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use of bone marrow transplantation has certainly not led to a significant improvement. New strategies such as the use of growth factors, inducers of differentiation (such as retinoic acid in M3) and improved supportive care may improve outcome, but AML continues to be a major challenge in paediatric oncology.
